Will Apitegromab (Isembyld) Build Muscle in Healthy Lifters?

In September 2026 the FDA approved the first drug that blocks myostatin. Within days the fitness press had decided what that meant. One headline promised a drug that "grows muscle without training". The forums filled up with the obvious question, and the search data shows exactly what people are typing: apitegromab for bodybuilding, apitegromab gym, apitegromab how to get.

So I read the label and the trials behind it. The honest answer is not the one anyone wants.

What Isembyld actually does

Isembyld (apitegromab-mstn) is a fully human IgG4 monoclonal antibody from Scholar Rock. The mechanism is narrower than the hype suggests, and the narrowness is the interesting part.

Myostatin is made as an inactive precursor. Your body produces promyostatin, which gets cleaved into a latent form, which then needs a second cleavage by a tolloid protease before the mature signalling molecule is released. Apitegromab binds the two inactive forms and stops that final activation step (Pirruccello-Straub et al., 2018). It never touches the mature protein.

Compare that with what the grey market has been selling for a decade. ACE-031 is a soluble receptor decoy: it mops up myostatin, but also activin A, GDF-11 and several bone morphogenetic proteins. Follistatin binds myostatin and activin A. Both are blunt instruments, and both have produced effects nobody wanted. Apitegromab is the first properly selective tool in this class to reach approval.

One quirk worth knowing if you ever see a myostatin result on a panel: total latent myostatin in serum goes up on treatment. That is drug-bound myostatin accumulating, not free myostatin rising. A rising number there means the drug is working, which is the opposite of the intuitive reading.

Who it is approved for, and what the trial actually showed

The label is specific. Isembyld is approved for spinal muscular atrophy in adults and children aged 2 and over who are already receiving an SMN2-targeted treatment, meaning nusinersen or risdiplam. It is an add-on, not a standalone. The dose is weight based, given intravenously every four weeks as a one to two hour infusion in a clinic. Company executives have put the net annual cost for a typical patient at about 310,000 US dollars, with the wholesale price reported at 11,659 US dollars per vial.

The pivotal trial was SAPPHIRE: 188 non-ambulatory patients with type 2 or 3 SMA, aged 2 to 21, all on existing therapy (Crawford et al., 2025). It followed the Phase 2 TOPAZ study in the same disease population (Crawford et al., 2024). The primary endpoint was the Hammersmith motor function scale.

Read this part carefully, because the published paper and the FDA label quote different numbers. The paper's primary analysis pooled both doses and found a 1.8 point advantage over placebo (95 percent CI 0.30 to 3.32). The label reports the approved 10 mg/kg dose separately: a 2.2 point difference, with treated patients improving 1.0 points while placebo declined 1.2. The higher 20 mg/kg dose on its own did not reach significance in the publication. The label describes these p-values as nominal, meaning they are not adjusted for multiple comparisons.

The scale runs to 66 points. So we are talking about two points on a 66 point scale, in children whose motor function was declining. That is a real result for them, because stopping a decline matters enormously when you have SMA. The responder analysis makes it clearer: 34.2 percent of treated patients gained at least 3 points, against 13.5 percent on placebo.

What it is not is evidence of hypertrophy. The endpoint was function in a disease population with a motor neuron deficit. Nobody measured muscle size in anyone with normal muscle.

Would it build muscle in a healthy lifter?

There is no trial that answers this, and that is not a gap in my research. It is the state of the evidence.

Apitegromab has been through a Phase 1 study in healthy volunteers, but it was a safety, pharmacokinetic and pharmacodynamic study (Barrett et al., 2021). It was designed to establish dosing and tolerability. It did not measure lean mass, muscle volume or strength, because that was not its job.

The closest thing we have in adults is EMBRAZE, published in Nature Medicine this year (Pratley et al., 2026). It randomised 102 adults with overweight or obesity to tirzepatide plus apitegromab or tirzepatide plus placebo for 24 weeks. The results:

• Lean mass loss was 1.9 kg smaller with apitegromab, which the authors frame as retaining about 55 percent of the lean mass that would otherwise have been lost.
• Lean tissue made up 14.6 percent of total weight lost, against 30.2 percent on tirzepatide alone.
• Total weight loss was about the same in both arms.
• Adverse events were comparable, 76 percent against 71 percent, with one serious event in each arm.

That is a good result, and it is the reason this drug matters to our audience at all. But read what it says. People who were losing weight lost less muscle while doing it. Nobody gained muscle. There is no arm in that trial where a well-fed person doing resistance training added tissue.

Two caveats on how it was reported. The lean mass endpoint used an 80 percent confidence interval rather than the conventional 95 percent, and the trial was sponsored by the manufacturer with company authors.

The third point is the one that should give you pause, and you will not find it in the abstract. The paper measured physical function as an exploratory endpoint, using handheld dynamometry for force production and a chair sit-to-stand test. Neither showed a notable difference from placebo. So the extra 1.9 kg of lean tissue did not translate into measurably more force or better function over 24 weeks. Preserving a kilogram of lean mass on a DXA scan and preserving the ability to use it are not the same claim, and in this trial they came apart.

Why a lifter is the wrong patient

Every population where myostatin blockade has shown benefit had something to correct. SMA patients have a motor neuron disease. The EMBRAZE participants were in an energy deficit on an appetite suppressant. In both cases the drug was defending tissue under attack.

A healthy lifter who eats enough and trains has no deficit of that kind. Myostatin is not what is limiting you. The thing that is limiting you is almost always training stimulus, protein intake, sleep and years under the bar. We have direct dose-response data on testosterone showing how much you get for a given hormonal push, and myostatin blockade has nothing remotely comparable in healthy adults.

The class has a long history of adding size without adding strength

This is the part the headline writers skip, and it is the single best reason for scepticism. Apitegromab is not the first drug to attack this pathway. It is the first to survive to approval.

Bimagrumab is the cautionary tale. In the older-adult cohort, which was the only one where body composition and strength were measured, a single dose measurably increased muscle volume and lean mass (Rooks et al., 2020). Fat mass fell too, though placebo fell by a similar amount, so I would not lean on that part. Strength did not follow. You can inflate a muscle's cross-section without improving what it does, which should bother anyone whose goal is performance rather than appearance.

Taldefgrobep went the same way: thigh muscle volume up in healthy volunteers, then a Duchenne programme that missed its functional endpoint (Muntoni et al., 2024).

ACE-031 is the one most lifters have heard of, because vials still circulate. It did raise lean mass by 3.3 percent and thigh muscle volume by 5.1 percent, in 48 healthy postmenopausal women (Attie et al., 2013). Then the Duchenne trial was halted over nosebleeds and dilated blood vessels in the skin, plausibly a consequence of the drug's untargeted binding across the whole TGF-beta family (Campbell et al., 2017). Development stopped. It was never approved for anything.

And follistatin, the compound with the most forum enthusiasm and the least oversight, has the ugliest entry in the table. Eleven bodybuilders using high-dose follistatin-344 presented with central serous chorioretinopathy, a fluid leak under the retina that degrades vision (Dağ et al., 2020). That is covered in more detail in our SARMs and peptides bloodwork guide.

The fracture signal, and the two numbers that get confused

Isembyld has no boxed warning. It does have a fractures warning, and the numbers get garbled everywhere I have seen them repeated, so here they are from the label.

In the pivotal trial, fractures occurred in 5 of 53 patients (9 percent) at the approved 10 mg/kg dose, 3 of 53 (6 percent) at 20 mg/kg, and 1 of 50 (2 percent) on placebo. Three femur fractures occurred on the drug. Separately, in the open-label extension at the higher dose, 22 patients (9 percent) had fractures, 5 of them serious femur fractures. Those are two different 9 percent figures from two different datasets, and most articles merge them into one.

Some fractures happened with no clear precipitating event. Animal studies also showed bone effects.

Here is the caveat: most of the affected patients already had low bone density, previous fractures or contractures. That is a population at high fracture risk before any drug. You cannot read the rate straight across to an adult with normal bone.

Here is the counterpoint: it is still a bone signal from a drug whose mechanism touches a pathway involved in bone turnover, and nobody has tested it in heavy adults putting large loads through their skeleton. If you train seriously, that is the opposite of a reassuring unknown.

Markers that would matter

If you were monitoring this class, the panel to watch is a bone and muscle panel rather than the usual hormonal one. ALP as a bone turnover signal, calcium and phosphate, PTH and vitamin D for the regulatory picture behind them, and creatine kinase for muscle damage. The trial data report asymptomatic CK rises.

This is not a validated monitoring protocol for apitegromab, because none exists. It is just the sensible panel given the mechanism and the warning. Bloodwork also will not tell you about bone density: that needs a DXA scan, and low oestradiol is a far more common reason for a lifter to have bad bone density, which is covered in how to fix crashed E2.

If you are on a GLP-1 and worried about lean mass

This is the real question underneath most of the apitegromab searches, and it has answers that exist today.

Losing muscle while losing weight is a genuine problem. In the retatrutide Phase 3 data, a meaningful share of the weight lost was lean tissue, which we broke down in how much muscle you lose on retatrutide. EMBRAZE put the figure for tirzepatide alone at about 30 percent of total weight lost. That is worth acting on.

What to do about it, in order of how well it is supported:

1. Resistance train through the deficit. Not cardio, not "staying active". Progressive loading is the only intervention with unambiguous evidence for defending lean mass in an energy deficit.
2. Keep protein high. Appetite suppression makes this hard, which is the practical trap of these drugs. Protein is the first thing to fall when you stop feeling like eating.
3. Slow the rate of loss. A smaller deficit costs you less lean tissue. Titrating a GLP-1 up until you barely eat is the fastest route to losing muscle with it.
4. Measure instead of guessing. Scale weight cannot distinguish fat from muscle. Get a DXA at the start and a few months in, and track your lifts, which is a free and surprisingly sensitive readout.

Compounds marketed as muscle sparing deserve the same scrutiny. I went through the evidence for one of them in does eloralintide protect muscle, and the answer was that nobody has measured it. MK-677 raises IGF-1 and weight, but much of the early gain is water, and it worsens insulin resistance. YK-11's myostatin mechanism exists only in a cell culture dish.

Practical recommendations

You cannot get Isembyld for muscle, and the maths is not close. It is a clinic-administered infusion, prescribed on a label that requires an SMA diagnosis and existing SMN2 therapy, at a net cost reported at about 310,000 US dollars a year. There is no realistic off-label route.

Anything sold to lifters as a myostatin inhibitor is not this drug. Antibodies listed by research reagent suppliers are catalogue material for laboratory use, not sterile injectable product, and the same contamination and dosing problems apply as to everything else in that market, which we covered in heavy metals in UGL steroids and peptides.

If the appeal was muscle preservation on a GLP-1, act on the four points above. They are free, they work, and they do not carry a fracture warning.

Follow the research, but keep your expectations honest. The interesting question is whether a selective myostatin blocker preserves lean mass in people dieting hard. EMBRAZE suggests it might. That is a legitimate medical use, studied in the right population. It has nothing to do with adding muscle to a healthy lifter.

Key takeaways

• Isembyld (apitegromab) was approved in September 2026 for spinal muscular atrophy, as an add-on for patients aged 2 and over already on an SMN2-targeted therapy. It is a clinic-administered IV infusion.
• It is the first selective myostatin blocker approved anywhere. It binds the inactive precursor forms and stops myostatin activation, which is cleaner than ACE-031 or follistatin.
• No study has measured muscle growth in a healthy adult. The Phase 1 in healthy volunteers had no muscle endpoint at all.
• The only adult efficacy data is lean mass preservation during tirzepatide weight loss: 1.9 kg less lean mass lost over 24 weeks, with no matching benefit on the trial's exploratory strength and sit-to-stand tests.
• The SAPPHIRE benefit was about 2 points on a 66 point motor scale in children with declining function. Meaningful for them, irrelevant as evidence of hypertrophy.
• The label warns of fractures: 9 percent at the approved dose against 2 percent on placebo, including femur fractures without clear cause, plus animal bone findings and reproductive cautions.
• Every predecessor in this class either raised muscle size without raising strength (bimagrumab, taldefgrobep) or was abandoned on safety grounds (ACE-031), and grey market follistatin produced retinal damage in bodybuilders.
• If you are losing muscle on a GLP-1, resistance training, protein, a slower deficit and actual body composition measurement are the interventions with evidence behind them.

---

References

1. Crawford, T. O., Servais, L., Mercuri, E., et al. (2025). Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurology, 24(9), 727-739. PubMed
2. Pratley, R. E., Denham, D. S., Trivedi, R., et al. (2026). Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial. Nature Medicine, 32(7), 2673-2678. PubMed
3. Pirruccello-Straub, M., Jackson, J., Wawersik, S., et al. (2018). Blocking extracellular activation of myostatin as a strategy for treating muscle wasting. Scientific Reports, 8(1), 2292. PubMed
4. Barrett, D., Bilic, S., Chyung, Y., et al. (2021). A randomized phase 1 safety, pharmacokinetic and pharmacodynamic study of the novel myostatin inhibitor apitegromab (SRK-015). Advances in Therapy, 38(6), 3203-3222. PubMed
5. Crawford, T. O., Darras, B. T., Day, J. W., et al. (2024). Safety and efficacy of apitegromab in patients with spinal muscular atrophy types 2 and 3: the phase 2 TOPAZ study. Neurology, 102(5), e209151. PubMed
6. Rooks, D., Praestgaard, J., Hariry, S., et al. (2020). Safety and pharmacokinetics of bimagrumab in healthy older and obese adults with body composition changes in the older cohort. Journal of Cachexia, Sarcopenia and Muscle, 11(6), 1525-1534. PubMed
7. Muntoni, F., Byrne, B. J., Mercuri, E., et al. (2024). The clinical development of taldefgrobep alfa: an anti-myostatin adnectin for the treatment of Duchenne muscular dystrophy. Neurology and Therapy, 13(1), 183-219. PubMed
8. Attie, K. M., Borgstein, N. G., Yang, Y., et al. (2013). A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle & Nerve, 47(3), 416-423. PubMed
9. Campbell, C., McMillan, H. J., Mah, J. K., et al. (2017). Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial. Muscle & Nerve, 55(4), 458-464. PubMed
10. Dağ, U., Çağlayan, M., Öncül, H., et al. (2020). Central serous chorioretinopathy associated with high-dose follistatin-344: a retrospective case series. International Ophthalmology, 40(11), 3155-3161. PubMed
11. U.S. Food and Drug Administration. (2026). ISEMBYLD (apitegromab-mstn) prescribing information (BLA 761463). Label PDF
12. U.S. Food and Drug Administration. (2026, September 11). FDA approves first therapy to target muscle loss in spinal muscular atrophy. FDA